Table 1 Demographic and baseline characteristics of the study patients
Benidipine plus ARB (n=1110) | Benidipine plus BB (n=1089) | Benidipine plus TD (n=1094) | |
|---|---|---|---|
Demographic | |||
Sex, male | 566 (51.0%) | 550 (50.5%) | 553 (50.5%) |
Age, years | 63.0±10.6 | 63.2±10.8 | 63.1±10.8 |
Baseline characteristics | |||
BMI, kg m–2 | 24.6±3.4 | 24.6±3.4 | 24.4±3.4 |
Systolic BP, mm Hg | 153.9±11.8 | 153.7±10.9 | 154.1±12.0 |
Diastolic BP, mm Hg | 89.0±9.8 | 88.7±9.6 | 88.7±9.8 |
Heart rate, beat min–1 | 74.0±11.0 | 74.2±11.1 | 74.2±11.5 |
Risk factors | |||
Previous cardiovascular disease | 144 (13.0%) | 124 (11.4%) | 137 (12.5%) |
Previous cerebrovascular disease | 50 ( 4.5%) | 36 ( 3.3%) | 40 ( 3.7%) |
Diabetes | 154 (13.9%) | 155 (14.2%) | 157 (14.4%) |
Dyslipidemia | 429 (38.6%) | 423 (38.8%) | 454 (41.5%) |
Current smoking | 436 (39.3%) | 431 (39.6%) | 435 (39.8%) |
Previous medication | |||
Antihypertensive agents | 891 (80.3%) | 869 (79.8%) | 872 (79.7%) |
Benidipine | 698 (62.9%) | 694 (63.7%) | 691 (63.2%) |
Other CCB | 129 (11.6%) | 115 (10.6%) | 120 (11.0%) |
ARB | 103 ( 9.3%) | 103 ( 9.5%) | 98 ( 9.0%) |
ACE inhibitor | 20 ( 1.8%) | 23 ( 2.1%) | 14 ( 1.3%) |
BB | 26 ( 2.3%) | 38 ( 3.5%) | 35 ( 3.2%) |
Diuretics | 12 ( 1.1%) | 8 ( 0.7%) | 13 ( 1.2%) |
Others | 10 ( 0.9%) | 10 ( 0.9%) | 3 ( 0.3%) |
Concomitant medication | |||
Anti-platelets | 99 ( 8.9%) | 74 ( 6.8%) | 80 ( 7.3%) |
Anticoagulants | 4 ( 0.4%) | 2 ( 0.2%) | 4 ( 0.4%) |
Lipid-lowering agents | 234 (21.1%) | 222 (20.4%) | 232 (21.2%) |
Statin | 189 (17.0%) | 185 (17.0%) | 178 (16.3%) |
Antidiabetic agents | 77 ( 6.9%) | 80 ( 7.3%) | 79 ( 7.2%) |
